JP7417231B2 - 抗インターフェロンγ抗体を検出するための免疫クロマトグラフィーによる方法及びキット - Google Patents
抗インターフェロンγ抗体を検出するための免疫クロマトグラフィーによる方法及びキット Download PDFInfo
- Publication number
- JP7417231B2 JP7417231B2 JP2022555985A JP2022555985A JP7417231B2 JP 7417231 B2 JP7417231 B2 JP 7417231B2 JP 2022555985 A JP2022555985 A JP 2022555985A JP 2022555985 A JP2022555985 A JP 2022555985A JP 7417231 B2 JP7417231 B2 JP 7417231B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- complex
- region
- ifn
- interferon gamma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003130 interferon gamma Drugs 0.000 title claims description 40
- 238000000034 method Methods 0.000 title claims description 39
- 230000001064 anti-interferon Effects 0.000 title claims description 12
- 108010074328 Interferon-gamma Proteins 0.000 claims description 111
- 238000012360 testing method Methods 0.000 claims description 91
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 51
- 210000001124 body fluid Anatomy 0.000 claims description 46
- 239000010839 body fluid Substances 0.000 claims description 46
- 238000006243 chemical reaction Methods 0.000 claims description 38
- 239000002904 solvent Substances 0.000 claims description 37
- 239000012071 phase Substances 0.000 claims description 35
- 230000000007 visual effect Effects 0.000 claims description 29
- 102000008070 Interferon-gamma Human genes 0.000 claims description 25
- 229960002685 biotin Drugs 0.000 claims description 25
- 235000020958 biotin Nutrition 0.000 claims description 25
- 239000011616 biotin Substances 0.000 claims description 25
- 239000007790 solid phase Substances 0.000 claims description 24
- 239000012528 membrane Substances 0.000 claims description 18
- 230000027455 binding Effects 0.000 claims description 14
- 230000001745 anti-biotin effect Effects 0.000 claims description 12
- 239000002250 absorbent Substances 0.000 claims description 9
- 230000002745 absorbent Effects 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 238000000151 deposition Methods 0.000 claims description 7
- 239000002096 quantum dot Substances 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 229920003043 Cellulose fiber Polymers 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 description 86
- 239000000523 sample Substances 0.000 description 47
- 238000002965 ELISA Methods 0.000 description 23
- 239000000758 substrate Substances 0.000 description 23
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 238000003118 sandwich ELISA Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 239000000427 antigen Substances 0.000 description 10
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 9
- 210000003000 inclusion body Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003317 immunochromatography Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 102000043557 human IFNG Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000014725 late viral mRNA transcription Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TH2001003762 | 2020-06-29 | ||
| TH2001003762 | 2020-06-29 | ||
| PCT/TH2021/000029 WO2022005408A1 (fr) | 2020-06-29 | 2021-06-04 | Procédé et kit immunochromatographique pour détecter un anticorps anti-interféron gamma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518742A JP2023518742A (ja) | 2023-05-08 |
| JP7417231B2 true JP7417231B2 (ja) | 2024-01-18 |
Family
ID=77022168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555985A Active JP7417231B2 (ja) | 2020-06-29 | 2021-06-04 | 抗インターフェロンγ抗体を検出するための免疫クロマトグラフィーによる方法及びキット |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP7417231B2 (fr) |
| CN (1) | CN115176157A (fr) |
| WO (1) | WO2022005408A1 (fr) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011528789A (ja) | 2008-07-18 | 2011-11-24 | ボストン メディカル センター コーポレーション | 膜性腎症の診断法 |
| US20170114112A1 (en) | 2015-06-18 | 2017-04-27 | Chang Gung University | Epitope recognized by anti-interferon gamma autoantibodies in patients with disseminated mycobacterial infections and the application therefor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231727B (it) * | 1989-08-11 | 1991-12-21 | Enrico Savoldi | Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone. |
| AU660837B2 (en) * | 1992-09-04 | 1995-07-06 | Becton Dickinson & Company | Indirect chromatographic antigen sandwich test for detection of specific antibody and device therefor |
| US20080138842A1 (en) * | 2006-12-11 | 2008-06-12 | Hans Boehringer | Indirect lateral flow sandwich assay |
| US20120220051A1 (en) * | 2009-07-08 | 2012-08-30 | Anp Technologies, Inc. | Immunogenicity Assay |
-
2021
- 2021-06-04 JP JP2022555985A patent/JP7417231B2/ja active Active
- 2021-06-04 CN CN202180017176.6A patent/CN115176157A/zh active Pending
- 2021-06-04 WO PCT/TH2021/000029 patent/WO2022005408A1/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011528789A (ja) | 2008-07-18 | 2011-11-24 | ボストン メディカル センター コーポレーション | 膜性腎症の診断法 |
| US20170114112A1 (en) | 2015-06-18 | 2017-04-27 | Chang Gung University | Epitope recognized by anti-interferon gamma autoantibodies in patients with disseminated mycobacterial infections and the application therefor |
Non-Patent Citations (2)
| Title |
|---|
| MADARIAGA, L. et al.，Detection of anti-interferon-gamma autoantibodies in subjects infected by Mycobacterium tuberculosis，The International Journal of Tuberculosis and Lung Disease，1998年，Vol.2, No.1，p.62-68 |
| YASAMUT, U. et al.，Neutralizing Activity of Anti-interferon-γ Autoantibodies in Adult-Onset Immunodeficiency Is Associated With Their Binding Domains，Front. Immunol.，2019年，Vol.10, No.1905，p.1-12，https://doi.org/10.3389/fimmu.2019.01905 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115176157A (zh) | 2022-10-11 |
| JP2023518742A (ja) | 2023-05-08 |
| WO2022005408A1 (fr) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111164095B (zh) | 用于改进分析物检测的测定方法 | |
| US5413913A (en) | Erythrocyte agglutination assay | |
| KR100620297B1 (ko) | ＮＴ―ｐｒｏＢＮＰ 측정용 분석 샌드위치 테스트 | |
| US9506913B2 (en) | Method of detecting surrogate markers in a serum sample | |
| KR102227648B1 (ko) | B형 인플루엔자 바이러스의 측정 방법 | |
| JPH07501403A (ja) | 改良された流体フローのための疎水性手段を含む検出装置 | |
| KR101782862B1 (ko) | 메르스바이러스 진단용 단세포군 항체 및 면역크로마토그래피 진단키트 | |
| TWI554759B (zh) | An immunochromatographic assay device, an immunochromatographic assay, and an immunochromatographic assay kit | |
| US20130224884A1 (en) | Device and method for immunoassays | |
| EP2796470A2 (fr) | Anticorps anti-peptide natriurétique canin liant specifiquement la partie N-terminale dudit peptide, utilisation desdits anticorps dans une méthode de mesure dudit peptide et kit pour réaliser cette méthode. | |
| US20210072235A1 (en) | Method for diagnosing tuberculosis | |
| US20230341392A1 (en) | Detection of antibodies to sars-cov2 | |
| JP7417231B2 (ja) | 抗インターフェロンγ抗体を検出するための免疫クロマトグラフィーによる方法及びキット | |
| US5583003A (en) | Agglutination assay | |
| AP156A (en) | Agglutination assay. | |
| JPH09500962A (ja) | 試験装置 | |
| EP0308242B1 (fr) | Essai d'agglutination | |
| KR101876535B1 (ko) | 소바이러스성 설사병 바이러스의 탐지용 항체, 이를 이용한 항원 검출 방법, 및 이를 포함하는 탐지키트 | |
| JP6505473B2 (ja) | 結核性胸膜炎診断剤 | |
| RU2741199C1 (ru) | Способ иммунохроматографической серодиагностики с последовательным добавлением реагентов | |
| RU2545909C2 (ru) | Способ иммунохроматографического определения специфических антител | |
| KR102404143B1 (ko) | 라싸 바이러스 핵단백질에 특이적인 항체, 이를 생산하는 하이브리도마 세포주 및 이를 이용한 라싸 바이러스 검출 키트 | |
| KR102021539B1 (ko) | 모기 매개 바이러스 진단용 펩타이드 및 이의 용도 | |
| KR102021540B1 (ko) | 모기 매개 바이러스 진단용 펩타이드 및 이의 용도 | |
| KR102021538B1 (ko) | 모기 매개 바이러스 진단용 펩타이드 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220916 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231121 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231212 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231222 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7417231 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |